Kadmon Holdings Inc. plans to sell its common shares in a public offering.
The company also intends to grant the underwriters an option to buy additional shares.
Kadmon plans to use the net proceeds for preclinical and clinical development of its lead product candidates. It also plans to use the proceeds for the discovery, research and preclinical studies of its other potential drugs and for other general corporate purposes.
Jefferies LLC is acting as the sole book-running manager, while H.C. Wainwright & Co. LLC is acting as the lead manager for the offering.
New York-based Kadmon Holdings is a biopharmaceutical company, which discovers, develops and commercializes small molecules and biologics primarily to treat inflammatory and fibrotic diseases.
